Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, June 14, 2021
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
[ Mon, Jun 14th 2021
] - WOPRAI
David Lebowitz Maintained (ASND) at Buy with Decreased Target to $197 on, Jun 14th, 2021
David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $201 to $197 on, Jun 14th, 2021.
David has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Tuesday, March 30th, 2021
These are the ratings of the 2 analyists that currently disagree with David
- Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, June 1st, 2021
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $178 on, Friday, May 28th, 2021
